Abstract
Objective Apolipoprotein E (APOE) interacts with AD pathology to promote disease progression. Studies of APOE risk primarily focus on amyloid, however, and little research has assessed its interaction with tau pathology independent of amyloid. The current study investigated the moderating effect of APOE genotype on independent associations of amyloid and tau PET with cognition.
Methods Participants included 297 older adults without dementia from the Alzheimer’s Disease Neuroimaging Initiative. Regression equations modeled associations between cognitive domains and (1) cortical Aβ PET levels adjusting for tau PET and (2) medial temporal lobe (MTL) tau PET levels adjusting for Aβ PET, including interactions with APOE ε4 carrier status.
Results Adjusting for tau PET, Aβ was not associated with cognition and did not interact with ε4 status. In contrast, adjusting for Aβ PET, MTL tau PET was significantly associated with all cognitive domains. Further, there was a moderating effect of ε4 status on MTL tau and memory with the strongest negative associations in ε4 carriers and at high levels of tau. This interaction persisted even among only Aβ negative individuals.
Interpretation APOE ε4 genotype strengthens the negative association between MTL tau and memory independently of Aβ, although the converse is not observed, and this association may be particularly strong at high levels of tau. These findings suggest that APOE may interact with tau independently of Aβ and that elevated MTL tau confers negative cognitive consequences in Aβ negative ε4 carriers.
Competing Interest Statement
Ms. Weigand, Dr. Bangen, Dr. Thomas, Dr. Eglit, Dr. Delano-Wood, Dr. Gilbert, and Dr. Brickman report no competing interests. Dr. Bondi receives royalties from Oxford University Press and serves as a consultant for Eisai, Novartis and Roche Pharmaceutical companies.
Funding Statement
This work was supported by NSF fellowship DGE-1650112 (A.J.W.) and NIH grants R01 AG049810 and R01 AG054049 (M.W.B.). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. This research was approved by the Institutional Review Boards of all participating sites, and written informed consent was obtained for all study participants.